Modest improvement of metabolic and behavioral deficits with long-term ambroxol treatment in a Pink1−/−SNCAA53T double mutant mouse model of Parkinson’s disease
Year: 2025
Type: article
Language: en
Topic: Parkinson's Disease Mechanisms and Treatments
Authors and affiliations:
raw_author_name: Luisa Franck
raw_affiliation_strings: Institute of Clinical Pharmacology, Goethe University Frankfurt, Faculty of Medicine, Frankfurt am Main, Germany
raw_author_name: Lucie Valek
raw_affiliation_strings: Institute of Clinical Pharmacology, Goethe University Frankfurt, Faculty of Medicine, Frankfurt am Main, Germany
raw_author_name: Lisa Hahnefeld
raw_affiliation_strings: Fraunhofer Institute for Translational Medicine and Pharmacology ITMP and Fraunhofer Cluster of Excellence for Immune Mediated Diseases CIMD, Frankfurt am Main, Germany
Institute of Clinical Pharmacology, Goethe University Frankfurt, Faculty of Medicine, Frankfurt am Main, Germany
raw_author_name: Sandra Trautmann
raw_affiliation_strings: Fraunhofer Institute for Translational Medicine and Pharmacology ITMP and Fraunhofer Cluster of Excellence for Immune Mediated Diseases CIMD, Frankfurt am Main, Germany
Institute of Clinical Pharmacology, Goethe University Frankfurt, Faculty of Medicine, Frankfurt am Main, Germany
raw_author_name: Carlo Angioni
raw_affiliation_strings: Fraunhofer Institute for Translational Medicine and Pharmacology ITMP and Fraunhofer Cluster of Excellence for Immune Mediated Diseases CIMD, Frankfurt am Main, Germany
Institute of Clinical Pharmacology, Goethe University Frankfurt, Faculty of Medicine, Frankfurt am Main, Germany
raw_author_name: Marc-Philipp Weyer
raw_affiliation_strings: Institute of Clinical Pharmacology, Goethe University Frankfurt, Faculty of Medicine, Frankfurt am Main, Germany
raw_author_name: Dominique Thomas
raw_affiliation_strings: Fraunhofer Institute for Translational Medicine and Pharmacology ITMP and Fraunhofer Cluster of Excellence for Immune Mediated Diseases CIMD, Frankfurt am Main, Germany
Institute of Clinical Pharmacology, Goethe University Frankfurt, Faculty of Medicine, Frankfurt am Main, Germany
raw_author_name: Robert Gurke
raw_affiliation_strings: Fraunhofer Institute for Translational Medicine and Pharmacology ITMP and Fraunhofer Cluster of Excellence for Immune Mediated Diseases CIMD, Frankfurt am Main, Germany
Institute of Clinical Pharmacology, Goethe University Frankfurt, Faculty of Medicine, Frankfurt am Main, Germany
raw_author_name: Ilka Wittig
raw_affiliation_strings: Functional Proteomics, Institute of Cardiovascular Physiology, Goethe-University Frankfurt, Faculty of Medicine, Frankfurt am Main, Germany
raw_author_name: Gerd Geisslinger
raw_affiliation_strings: Fraunhofer Institute for Translational Medicine and Pharmacology ITMP and Fraunhofer Cluster of Excellence for Immune Mediated Diseases CIMD, Frankfurt am Main, Germany
Institute of Clinical Pharmacology, Goethe University Frankfurt, Faculty of Medicine, Frankfurt am Main, Germany
raw_author_name: Irmgard Tegeder
raw_affiliation_strings: Institute of Clinical Pharmacology, Goethe University Frankfurt, Faculty of Medicine, Frankfurt am Main, Germany. tegeder@em.uni-frankfurt.de
Institute of Clinical Pharmacology, Goethe University Frankfurt, Faculty of Medicine, Frankfurt am Main, Germany